Patents by Inventor Darryl Rideout

Darryl Rideout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220185785
    Abstract: Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.
    Type: Application
    Filed: April 13, 2020
    Publication date: June 16, 2022
    Applicant: TONIX PHARMACEUTICALS HOLDING CORP
    Inventors: Darryl RIDEOUT, Seth LEDERMAN
  • Publication number: 20210139959
    Abstract: In various embodiments, a signal enhancement process for single molecule molecular sensors is disclosed along with new modified dNTPs. In general, the enhancement process comprises providing a molecular electronic sensor comprising a polymerase and providing a nucleotide template and modified dNTPs in appropriate buffers to the polymerase, wherein incorporation of the modified dNTPs during action of the polymerase enzyme provides an enhanced electrical signal or improved signal-to-noise ratio for the incorporation event relative to the performance with corresponding native dNTPs.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 13, 2021
    Inventors: Barry L. Merriman, Tim Geiser, Paul W. Mola, Darryl Rideout
  • Publication number: 20200230104
    Abstract: The present invention relates to cyclobenzaprine analogs useful for treatment or prevention of symptoms associated with post-traumatic stress disorder.
    Type: Application
    Filed: July 13, 2018
    Publication date: July 23, 2020
    Applicant: Tonix Pharmaceuticals Holding Corp
    Inventors: Seth Lederman, Darryl Rideout, Greg Sullivan
  • Publication number: 20190284211
    Abstract: The present invention provides cryptates with excellent fluorescent properties. The cryptates are useful in biological assays and methods for the detection and identification of various analytes.
    Type: Application
    Filed: May 6, 2019
    Publication date: September 19, 2019
    Applicant: NESTEC S.A.
    Inventors: Michael Hale, Darryl Rideout, Raj Srikrishnan, Stefan Westin, David Schmit
  • Patent number: 9403755
    Abstract: The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH).
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 2, 2016
    Assignee: TONIX PHARMA HOLDINGS LIMITED (BERMUDA)
    Inventors: Seth Lederman, Bruce Daugherty, Leland J. Gershell, Darryl Rideout, Andrew Kawasaki
  • Publication number: 20140212486
    Abstract: The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH).
    Type: Application
    Filed: January 17, 2014
    Publication date: July 31, 2014
    Applicant: TONIX PHARMACEUTICALS INC.
    Inventors: SETH LEDERMAN, BRUCE DAUGHERTY, LELAND J. GERSHELL, DARRYL RIDEOUT, ANDREW KAWASAKI
  • Publication number: 20080200371
    Abstract: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.
    Type: Application
    Filed: March 28, 2008
    Publication date: August 21, 2008
    Inventors: Zacharia S. CHERUVALLATH, Colin J. Loweth, Ruth F. Nutt, Darryl Rideout, Joseph E. Semple, Jing Wang, Feiyue Wu, Shankari Mylvaganam, Hengyi Zhu, Jianzhong Sun
  • Patent number: 7381736
    Abstract: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: June 3, 2008
    Assignee: Metabasis Therapeutics, Inc.
    Inventors: Zacharia S. Cheruvallath, Colin J. Loweth, Ruth F. Nutt, Darryl Rideout, Joseph E. Semple, Jing Wang, Feiyue Wu, Shankari Mylvaganam, Hengyi Zhu, Jianzhong Sun
  • Publication number: 20080070867
    Abstract: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. The compounds for use in the compositions and methods provided herein have formulae (I) Protein tyrosine phosaphatase, including PTB-IB, mediated diseases and disorders include diabetes including Type 1 and Type 2 diabetes (and associated complications such as hypertension, ischemic diseases of the large and small blood vessels, blindness, circulatory problems, kidney failure and atherosclerosis), syndrome X, metabolic syndrome, glucose intolerance, insulin resistance, obesity, cancer, and neurodegenerative diseases.
    Type: Application
    Filed: January 17, 2006
    Publication date: March 20, 2008
    Applicant: Metabasis Therapeutics, Inc.
    Inventors: Zacharia Cheruvallath, Joseph Semple, Vasanthakumar Rajappan, Darryl Rideout, Venkatachalapathi Yalamoori, Chung-Ying Tsai, Feiyue Wu, Lars Thoresen, Mark Shenderovich
  • Publication number: 20070197577
    Abstract: Methods, compounds and compositions for preventing and treating anthrax infections by inhibiting Anthrax Lethal Factor (LF) activity.
    Type: Application
    Filed: March 17, 2004
    Publication date: August 23, 2007
    Applicant: Cengent Therapeutics
    Inventors: Darryl Rideout, Tseitin Vladimir, Mark Shenderovich, Edward Semple, Ruth Nutt, Yalamoori Venkatachalapathl, Tsai Chung-Ying, Michelle De Luna, Thomas Brady, Feiyue Wu
  • Publication number: 20060194768
    Abstract: Compounds and compositions are provided for modulating the activity of protein tyrosine phosphatases. In one embodiment, the compounds and compositions are thiazoles and thiadiazoles that inhibit the activity of protein tyrosine phosphatase 1B.
    Type: Application
    Filed: September 2, 2005
    Publication date: August 31, 2006
    Inventors: Zacharia Cheruvallath, Colin Loweth, Ruth Nutt, Darryl Rideout, Joseph Semple, Jing Wang, Feiyue Wu, Shankari Mylvaganam, Hengyi Zhu, Jianzhong Sun
  • Publication number: 20060135773
    Abstract: Compounds, compositions and methods are provided for modulating the activity of protein tyrosine phosphatases, including PTP-1B. In one embodiment, the compounds are N,N-dibenzylarylsulfonamides.
    Type: Application
    Filed: June 17, 2005
    Publication date: June 22, 2006
    Inventors: Joseph Semple, Darryl Rideout, Ruth Nutt, Mark Shenderovich, Jing Wang, Shankari Mylvaganam, Feiyue Wu, Chung Tsai, Venkatachalapathi Yalamoori, Colin Loweth
  • Publication number: 20050065118
    Abstract: Organosulfur modulators of tyrosine phosphatases and their use in the treatment of disease are disclosed.
    Type: Application
    Filed: October 16, 2002
    Publication date: March 24, 2005
    Inventors: Jing Wang, Darryl Rideout, Kalyanaraman Ramnarayan, Chung-Ying Tsai, Venkatachalapathi Yalamoori, Feiyue Wu, Colin Loweth, Hassan ElAbdellaoui, Leah Fung, Thomas Brady
  • Patent number: 6825226
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoicacid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: November 30, 2004
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Publication number: 20030073745
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoicacid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Application
    Filed: June 24, 2002
    Publication date: April 17, 2003
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 6462064
    Abstract: The invention relates to the discovery that specific adamantyl or adamantyl group derivatives containing retinoid-related compounds induce apoptosis of cancer cells and therefore may be used for the treatment of cancer, including advanced cancer. Also, the present invention relates to novel adamantyl or adamantyl group derivatives containing retinoid compounds and their usage for treatment and/or prevention of cancer, keratinization disorders, dermatological conditions, and other therapies More specifically, it has been shown that such adamantyl compounds, e.g., 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to treat or prevent cervical cancers and precancers such as cervical dysplasias, including high grade and low grade dysplasias.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: October 8, 2002
    Assignee: Galderma Research & Development S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 6436933
    Abstract: Methods and compositions that act as specific inhibitors of ALF activity for the prophylaxis and treatment of anthrax infections.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: August 20, 2002
    Assignee: Structural Bioinformatics Inc.
    Inventors: Darryl Rideout, Venkatachalapathi V. Yalamoori, Kalyanaraman Ramnarayan, Mark Shenderovich, Jian Hua Zheng, Jason Sun, Christina Niemeyer
  • Patent number: 6127415
    Abstract: The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma/glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: October 3, 2000
    Assignee: Galderma Research & Development, S.N.C.
    Inventors: Magnus Pfahl, Xian-Ping Lu, Darryl Rideout, Hongyue Zhang
  • Patent number: 4699903
    Abstract: Use of the novel compound tin diiododeuteroporphyrin and compositions containing it to inhibit heme mebabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme and iron are excreted by mammals.
    Type: Grant
    Filed: January 29, 1987
    Date of Patent: October 13, 1987
    Assignee: The Rockefeller University
    Inventors: Darryl Rideout, Attallah Kappas, George S. Drummond
  • Patent number: 4692439
    Abstract: Use of the novel compound tin diiododeuteroporphyrin and compositions containing it to inhibit heme metabolism in mammals, to control the rate of tryptophan metabolism in mammals, and to increase the rate at which heme and iron are excreted by mammals.
    Type: Grant
    Filed: January 29, 1987
    Date of Patent: September 8, 1987
    Assignee: The Rockefeller University
    Inventors: Darryl Rideout, Attallah Kappas, George S. Drummond